About Nicholas Piramal
- India's fourth Largest Pharmaceutical Company with a Sales of $319mn
- Nicholas Piramal has acquired Rhodia’s global Inhalation Anaesthetics business. This acquisition gives NPIL access to the manufacturing technology and facilities, as well as the global sales and marketing rights for two Inhalation Anaesthetics products - Halothane and Isofluorane. NPIL will gain complete access to Rhodia’s sales and marketing network of exclusive pharma distributors in over 90 countries – – including the U.S., Europe, Japan, Australia and numerous emerging markets.
- Most successful track record in India with respect to joint ventures, product licensing and strategic alliances, based on mutual trust and understanding, leading to win-win partnerships
- One of the strongest marketing / distribution infrastructure in the Indian healthcare market
- 14 focused divisions and a streamlined supply chain with 4300 wholesalers and a cold chain facility.
- History of honouring agreements in letter and spirit
- Best track record among domestic companies in respecting Intellectual Properties Right (IPR)
- World class research & development centre in Mumbai
- State-of-the-art manufacturing facilities
- Long term alliance for supply of API & formulation for global requirements of the Innovator
- Best represented in policy making bodies in India
